Cizzle Biotechnology Holdings Plc (CIZ.L) Research

Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.

Market snapshot

Symbol
CIZ.L
Price
$2.80
Day change
-1.75%
Market cap
$11.9M
P/E ratio
-16.47x
52-week range
1.2-3.9
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Recent news

  • FTSE 100 Live: London stocks surge, Wall St volatile as SpaceX trading nears

    FTSE 100 jumps 162 points to 10,466 Brent crude futures fall then rise UK economy contracts 0.1% in April  Housebuilders show strong recovery   4.17pm:...

  • FTSE 100 Live: Stocks jump over 100 points on peace deal hopes, sending oil below $87

    FTSE 100 jumps 109 points to 10,413 Brent crude futures fall 2% UK economy contracts 0.1% in April  Housebuilders show strong recovery 11.54am: Shell, BP...

Peer companies

  • Cambridge Nutritional Sciences plc (CNSL.L)
  • CRISM Therapeutics Corporation (CRTX.L)
  • Futura Medical plc (FUM.L)
  • Genedrive Plc (GDR.L)
  • Genflow Biosciences plc (GENF.L)
  • Oxford BioDynamics Plc (OBD.L)
  • OptiBiotix Health Plc (OPTI.L)
  • Roquefort Therapeutics plc (ROQ.L)

Open Cizzle Biotechnology Holdings Plc (CIZ.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.